Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783667 | 0.89 | GPR119 (0.44) | GPR119USP30JAK2JAK1GLS | |
| SCHEMBL29365972 | 0.89 | GPR119 (0.44) | GPR119USP30JAK2JAK1GLS | |
| SCHEMBL21783763 | 0.89 | GPR119 (0.44) | GPR119USP30JAK2JAK1GLS | |
| SCHEMBL1329227 | 0.81 | GPR119 (0.48) | GPR119GLSKDM4EPKMALDH1A1 | |
| SCHEMBL23826388 | 0.79 | MAPT (0.34) | GPR119MAPTALDH1A1 | |
| SCHEMBL21777330 | 0.79 | MAPT (0.34) | GPR119MAPTALDH1A1 | |
| SCHEMBL21856528 | 0.79 | MAPT (0.34) | GPR119MAPTALDH1A1 | |
| SCHEMBL16545031 | 0.78 | NR1H2 (0.49) | GPR119JAK2JAK1GLSMAPT | |
| SCHEMBL34474175 | 0.77 | GPR119 (0.46) | GPR119USP30JAK2JAK1GLS | |
| SCHEMBL31209154 | 0.77 | GPR119 (0.46) | GPR119USP30JAK2JAK1GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | ITGB6, ITGA6, GP6 | GPR119 1240/4885USP30 3928/4885JAK2 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.